^
    Back
    Association details:
    Biomarker:ALK translocation
    Cancer:Non Small Cell Lung Cancer
    Regimen: (paclitaxel + Tecentriq (atezolizumab) + Avastin (bevacizumab) + carboplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Clin Oncol
    Title:

    A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

    Published date:
    10/20/2023
    Excerpt:
    A total of 228 patients with activating EGFR mutation (n=215) or ALK translocation (n=13) were enrolled from 16 sites in the Republic of Korea and randomized at 2:1 ratio to either ABCP (n=154) or PC arm (n=74….Objective response rates (69.5% vs 41.9%, P <0.001) and median PFS (8.48 vs. 5.62 months, hazard ratio [HR] 0.62 [0.45-0.86], P=0.004) were significantly better in the ABCP than PC arm.
    DOI:
    10.1200/JCO.23.01891